Could a common antibiotic boost chemo for tough breast cancer?
NCT ID NCT04722978
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial is testing whether adding the antibiotic moxifloxacin to standard chemotherapy (gemcitabine and carboplatin) helps people with metastatic triple-negative breast cancer live longer without their cancer growing. About 228 participants will receive either the antibiotic or a placebo alongside chemo. The goal is to see if this combination improves progression-free survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
moxifloxacin (an antibiotic) plus gemcitabine and carboplatin (standard chemotherapy)
What this could lead to
If it works, this could offer a new, affordable first-line treatment option for metastatic triple-negative breast cancer by boosting the effectiveness of standard chemotherapy.
What could go wrong
This is a phase 3 trial, but adding an antibiotic to chemo may not improve survival and could increase side effects like nausea or antibiotic resistance. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510060, China
Contact Phone: •••-•••-•••• Email: •••••@•••••